CLARITEV CORP (CTEV) Stock Fundamental Analysis

USA • New York Stock Exchange • NYSE:CTEV • US62548M2098

22.15 USD
-1.64 (-6.89%)
Last: Feb 10, 2026, 03:33 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CTEV. CTEV was compared to 35 industry peers in the Health Care Technology industry. CTEV may be in some trouble as it scores bad on both profitability and health. CTEV has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • CTEV had negative earnings in the past year.
  • CTEV had a positive operating cash flow in the past year.
  • CTEV had negative earnings in 4 of the past 5 years.
  • CTEV had a positive operating cash flow in each of the past 5 years.
CTEV Yearly Net Income VS EBIT VS OCF VS FCFCTEV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -500M -1B -1.5B

1.2 Ratios

  • CTEV has a Return On Assets of -6.85%. This is in the better half of the industry: CTEV outperforms 65.71% of its industry peers.
  • With a decent Return On Invested Capital value of 0.82%, CTEV is doing good in the industry, outperforming 62.86% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for CTEV is below the industry average of 6.63%.
Industry RankSector Rank
ROA -6.85%
ROE N/A
ROIC 0.82%
ROA(3y)-13.68%
ROA(5y)-9.22%
ROE(3y)-665.39%
ROE(5y)-402.43%
ROIC(3y)2.41%
ROIC(5y)N/A
CTEV Yearly ROA, ROE, ROICCTEV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

  • CTEV has a Operating Margin of 5.21%. This is in the better half of the industry: CTEV outperforms 68.57% of its industry peers.
  • CTEV's Operating Margin has declined in the last couple of years.
  • Looking at the Gross Margin, with a value of 74.72%, CTEV is in the better half of the industry, outperforming 74.29% of the companies in the same industry.
  • CTEV's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 5.21%
PM (TTM) N/A
GM 74.72%
OM growth 3Y-33.57%
OM growth 5Y-22.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.14%
GM growth 5Y-2.61%
CTEV Yearly Profit, Operating, Gross MarginsCTEV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • CTEV has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for CTEV remains at a similar level compared to 1 year ago.
  • CTEV has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, CTEV has a worse debt to assets ratio.
CTEV Yearly Shares OutstandingCTEV Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 200M 400M 600M
CTEV Yearly Total Debt VS Total AssetsCTEV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.2 Solvency

  • Based on the Altman-Z score of -0.38, we must say that CTEV is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -0.38, CTEV perfoms like the industry average, outperforming 45.71% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -0.38
ROIC/WACC0.13
WACC6.31%
CTEV Yearly LT Debt VS Equity VS FCFCTEV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B 5B

2.3 Liquidity

  • A Current Ratio of 1.21 indicates that CTEV should not have too much problems paying its short term obligations.
  • CTEV's Current ratio of 1.21 is on the low side compared to the rest of the industry. CTEV is outperformed by 77.14% of its industry peers.
  • CTEV has a Quick Ratio of 1.21. This is a normal value and indicates that CTEV is financially healthy and should not expect problems in meeting its short term obligations.
  • CTEV's Quick ratio of 1.21 is on the low side compared to the rest of the industry. CTEV is outperformed by 71.43% of its industry peers.
Industry RankSector Rank
Current Ratio 1.21
Quick Ratio 1.21
CTEV Yearly Current Assets VS Current LiabilitesCTEV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • CTEV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 67.52%, which is quite impressive.
  • Looking at the last year, CTEV shows a small growth in Revenue. The Revenue has grown by 0.89% in the last year.
  • Measured over the past years, CTEV shows a decrease in Revenue. The Revenue has been decreasing by -1.09% on average per year.
EPS 1Y (TTM)67.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.56%
Revenue 1Y (TTM)0.89%
Revenue growth 3Y-5.92%
Revenue growth 5Y-1.09%
Sales Q2Q%6.71%

3.2 Future

  • The Earnings Per Share is expected to grow by 22.00% on average over the next years. This is a very strong growth
  • CTEV is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.76% yearly.
EPS Next Y76.25%
EPS Next 2Y34.14%
EPS Next 3Y22%
EPS Next 5YN/A
Revenue Next Year2.9%
Revenue Next 2Y3.33%
Revenue Next 3Y3.76%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CTEV Yearly Revenue VS EstimatesCTEV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M 1B
CTEV Yearly EPS VS EstimatesCTEV Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 0 -20 -40 -60 -80

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • CTEV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CTEV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CTEV Price Earnings VS Forward Price EarningsCTEV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CTEV indicates a rather cheap valuation: CTEV is cheaper than 82.86% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 10.13
CTEV Per share dataCTEV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -100 -200

4.3 Compensation for Growth

  • CTEV's earnings are expected to grow with 22.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.14%
EPS Next 3Y22%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • CTEV does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CLARITEV CORP

NYSE:CTEV (2/10/2026, 3:33:53 PM)

22.15

-1.64 (-6.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)11-07
Earnings (Next)02-23
Inst Owners48.15%
Inst Owner ChangeN/A
Ins Owners6.93%
Ins Owner Change0.47%
Market Cap366.14M
Revenue(TTM)951.00M
Net Income(TTM)-341.68M
Analysts84.44
Price Target66.1 (198.42%)
Short Float %9.9%
Short Ratio4.32
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.42%
Min EPS beat(2)-15.41%
Max EPS beat(2)2.57%
EPS beat(4)2
Avg EPS beat(4)-5.44%
Min EPS beat(4)-23.58%
Max EPS beat(4)14.65%
EPS beat(8)4
Avg EPS beat(8)-188.45%
EPS beat(12)6
Avg EPS beat(12)-288.48%
EPS beat(16)7
Avg EPS beat(16)-215.53%
Revenue beat(2)2
Avg Revenue beat(2)2.38%
Min Revenue beat(2)2.26%
Max Revenue beat(2)2.51%
Revenue beat(4)3
Avg Revenue beat(4)0.94%
Min Revenue beat(4)-2.88%
Max Revenue beat(4)2.51%
Revenue beat(8)3
Avg Revenue beat(8)-1.92%
Revenue beat(12)5
Avg Revenue beat(12)-1.32%
Revenue beat(16)7
Avg Revenue beat(16)-1.84%
PT rev (1m)-26.64%
PT rev (3m)-15.48%
EPS NQ rev (1m)4.38%
EPS NQ rev (3m)-9.2%
EPS NY rev (1m)0.15%
EPS NY rev (3m)-2.99%
Revenue NQ rev (1m)-0.04%
Revenue NQ rev (3m)1.37%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)1.41%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.39
P/FCF N/A
P/OCF 20.74
P/B N/A
P/tB N/A
EV/EBITDA 10.13
EPS(TTM)-20.48
EYN/A
EPS(NY)-13.97
Fwd EYN/A
FCF(TTM)-6.79
FCFYN/A
OCF(TTM)1.07
OCFY4.82%
SpS57.53
BVpS-6.16
TBVpS-270.62
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -6.85%
ROE N/A
ROCE 1.04%
ROIC 0.82%
ROICexc 0.83%
ROICexgc 10.68%
OM 5.21%
PM (TTM) N/A
GM 74.72%
FCFM N/A
ROA(3y)-13.68%
ROA(5y)-9.22%
ROE(3y)-665.39%
ROE(5y)-402.43%
ROIC(3y)2.41%
ROIC(5y)N/A
ROICexc(3y)2.48%
ROICexc(5y)N/A
ROICexgc(3y)66.67%
ROICexgc(5y)N/A
ROCE(3y)3.05%
ROCE(5y)N/A
ROICexgc growth 3Y-40.96%
ROICexgc growth 5Y-27.14%
ROICexc growth 3Y-26.84%
ROICexc growth 5Y-14.89%
OM growth 3Y-33.57%
OM growth 5Y-22.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.14%
GM growth 5Y-2.61%
F-Score6
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 9.38
Cap/Depr 29.31%
Cap/Sales 13.65%
Interest Coverage 0.14
Cash Conversion 3.59%
Profit Quality N/A
Current Ratio 1.21
Quick Ratio 1.21
Altman-Z -0.38
F-Score6
WACC6.31%
ROIC/WACC0.13
Cap/Depr(3y)25.06%
Cap/Depr(5y)22.79%
Cap/Sales(3y)10.77%
Cap/Sales(5y)9.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)67.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.56%
EPS Next Y76.25%
EPS Next 2Y34.14%
EPS Next 3Y22%
EPS Next 5YN/A
Revenue 1Y (TTM)0.89%
Revenue growth 3Y-5.92%
Revenue growth 5Y-1.09%
Sales Q2Q%6.71%
Revenue Next Year2.9%
Revenue Next 2Y3.33%
Revenue Next 3Y3.76%
Revenue Next 5YN/A
EBIT growth 1Y-61.12%
EBIT growth 3Y-37.5%
EBIT growth 5Y-23.25%
EBIT Next Year145.66%
EBIT Next 3Y35.59%
EBIT Next 5YN/A
FCF growth 1Y-263.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-89.72%
OCF growth 3Y-35.69%
OCF growth 5Y-17.66%

CLARITEV CORP / CTEV FAQ

Can you provide the ChartMill fundamental rating for CLARITEV CORP?

ChartMill assigns a fundamental rating of 2 / 10 to CTEV.


What is the valuation status of CLARITEV CORP (CTEV) stock?

ChartMill assigns a valuation rating of 1 / 10 to CLARITEV CORP (CTEV). This can be considered as Overvalued.


What is the profitability of CTEV stock?

CLARITEV CORP (CTEV) has a profitability rating of 3 / 10.


What is the earnings growth outlook for CLARITEV CORP?

The Earnings per Share (EPS) of CLARITEV CORP (CTEV) is expected to grow by 76.25% in the next year.